Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Domestic business was up 41.9% YoY and 27.7% QoQ
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
The company reports revenue growth of 26% and PAT growth of 21% YoY
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
Demand normalisation post the second wave contributed to the steady growth
It works as an adjunct to standard care based on robust clinical trials
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Subscribe To Our Newsletter & Stay Updated
